ArticleFrontiers in pharmacology2026
Senkyunolide I and Danshensu in combination ameliorate post-MI myocardial fibrosis by regulating
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Myocardial fibrosis following myocardial infarction (MI) is a critical determinant of long-term clinical outcomes in heart disease. However, this central pathological process in the progression from MI to heart failure is not fully understood, posing challenges for targeted therapeutic options. Purpose: This study aimed to identify new targets critical to myocardial fibrosis after MI and to evaluate the potential of Guanxinning injection (GXNI, a combination of Danshen and Chuanxiong) to suppress post-MI myocardial fibrosis. Methods: A MI mouse model was established by permanent ligation of the left anterior descending artery. Therapeutic effects were assessed by echocardiography and histopathology. HPLC chromatography, Network pharmacology, molecular docking, two-dimensional primary cell cultures, and iPS-induced cardiac organoid models were employed to identify active components and investigate underlying mechanisms. Results: GXNI reduced myocardial fibrosis and injury, improving cardiac function. Network pharmacology and molecular docking identified Senkyunolide I (SENI) and Danshensu (DSS) as the key active components acting via the TGF-β1/PAI-1 pathway. Thermal shift assay demonstrated direct binding of SENI and DSS to PAI-1. Conclusion: We demonstrate for the first time that the TGF-β1/PAI-1 signaling pathway plays a critical role in post-MI myocardial fibrosis, and GXNI attenuates MI via this pathway. Secondly, the active components of GXNI, SENI and DSS, act combinatorially to enhance the anti-fibrotic therapeutic efficacy. Furthermore, cryoinjury cardiac organoids serve as a powerful platform for investigating the mechanisms underlying myocardial infarction.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.